Journals / Türk Oftalmoloji Dergisi / 2016 / Cilt: 46 - Sayı: 1

Clinical Findings, Follow-up and Treatment Results in Patients with Ocular Rosacea

Oküler Rozasea Olgularında Klinik Bulgular ve Takip-Tedavi Sonuçlarımız

Pages
1–6
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The increases in Schirmer's test and BUT were 3.3±1.5 and 4.5±2.8, respectively (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To report the clinical features, treatment options and complications in patients with ocular rosacea.Materials and Methods: The records of 48 eyes of 24 patients with ocular rosacea were retrospectively reviewed.
📊
Key Findings & Data:Patients' ocular signs and symptoms were scored between 1 and 4 points according to disease severity; tear film break-up time (BUT) and Schirmer's test results were recorded before and after the treatment.
💡
Conclusion & Impact:The increases in Schirmer's test and BUT were 3.3±1.5 and 4.5±2.8, respectively (p
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: To report the clinical features, treatment options and complications in patients with ocular rosacea.Materials and Methods: The records of 48 eyes of 24 patients with ocular rosacea were retrospectively reviewed. Patients' ocular signs and symptoms were scored between 1 and 4 points according to disease severity; tear film break-up time (BUT) and Schirmer's test results were recorded before and after the treatment. Preservative-free artificial tears, topical antibiotic eye drops/ointments, short-term topical corticosteroids, topical 0.05% cyclosporine and oral doxycycline treatment were applied as a standard therapy to all patients. Additional treatments were given as needed. Complications were recorded.Results: Twenty-four patients with a mean age of 48.5±35.4 years were followed for a mean 15±9.4 months. Ocular findings included meibomitis in 100% of cases, anterior blepharitis in 83% (40 eyes), punctate keratopathy in 67% (32 eyes), chalazia in 50% (24 eyes), corneal neovascularization in 50% (24 eyes) and subepithelial infiltrates in 16.6% (8 eyes). Significant improvement of symptoms and clinical findings were achieved in all patients with treatment. The increases in Schirmer's test and BUT were 3.3±1.5 and 4.5±2.8, respectively (p

Özet

Amaç: Oküler rozasealı olguların klinik özelliklerini, uygulanan tedavi seçeneklerini ve komplikasyonlarını bildirmektir.Gereç ve Yöntem: Oküler rozasea tanısı ile takip edilen 24 hastanın 48 gözüne ait veriler retrospektif olarak değerlendirildi. Hastaların tedavi öncesi ve takip sonundaki gözyaşı kırılma zamanı (GKZ) ve Schirmer testleri kaydedildi; göz belirti (yanma-batma, kızarıklık) ve bulguları (meibomit, konjonktival hiperemi, kornea bulguları) ciddiyete göre 1-4 puan arasında puanlandırıldı. Standart tedavi olarak suni gözyaşı, topikal antibiyotikli pomad, kısa süreli topikal kortikosteroid damla, topikal siklosporin %0,05 damla ve oral doksisiklin tedavisi uygulandı. Gerekli durumlarda yapılan ek tedaviler ve komplikasyonlar kaydedildi. Bulgular: Ortalama takip süresi 15±9,4 ay olan 24 hastanın ortalama yaşı 48,5±35,4 idi. Gözlerin tümünde meibomit (%100), %83'ünde ön blefarit varken (40 göz), %67'sinde punktat keratopati (32 göz), %50'sinde (24 hasta) şalazyon, %50'sinde (24 göz) kornea neovaskülarizasyonu, %16,6'sında (8 göz) periferik kornea infiltratları mevcuttu. Tedaviyle tüm göz bulgu ve belirtileri anlamlı derecede azaldı (p

🔖

Cite This Article

AKOVA, Y. A., MÜFTÜOĞLU, İ. K. (2022). Clinical Findings, Follow-up and Treatment Results in Patients with Ocular Rosacea. Türk Oftalmoloji Dergisi, Cilt: 46 - Sayı: 1, 1–6. https://ajindex.com/articles/637915

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Stone DU, Chodosh J. Ocular rosacea: an update on pathogenesis and therapy. Curr Opin Ophthalmol. 2004;15:499-502.
  2. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis and subtype classification. J Am Acad Dermatol. 2004;51:327-341; quiz 342-4.
  3. Ghanem VC, Mehra N, Wong S, Mannis MJ. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea. 2003;22:230-233.
  4. Çetinkaya A, Akova YA. Pediatric ocular acne rosacea: long-term treatment with systemic antibiotics. Am J Ophthalmol. 2006;142:816-821.
  5. Akpek EK, Merchant A, Pinar V, Foster CS. Ocular rosacea: patient characteristics and follow-up. Ophthalmology. 1997;104:1863-1867.
  6. Fallen RS, Gooderham M. Rosacea: update on management and emerging therapies. Skin Therapy Lett. 2012;17:1-4.
  7. Two AM, Del Rosso JQ. Kallikrein 5-mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit. J Clin Aesthet Dermatol. 2014;7:20-25.
  8. Sobolewska B, Doycheva D, Deuter C, Pfeffer I, Schaller M, Zierhut M. Treatment of ocular rosacea with once-daily low-dose doxycycline. Cornea. 2014;33:257-260.
  9. Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther. 2009;26:651-659.
  10. Frucht-Pery J, Sagi E, Hemo I, Ever-Hadani P. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol. 1993;116:88-92.
  11. Barnhorst DA Jr, Foster JA, Chern KC, Meisler DM. The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology. 1996;103:1880-1883.
  12. Souchier M, Joffre C, Gregoire S, Bretillon L, Muselier A, Acar N, Beynat J, Bron A, D'Athis P, Creuzot-Garcher C. Changes in meibomian fatty acids and clinical signs in patients with meibomian gland dysfunction after minocycline treatment. Br J Ophthalmol. 2008;92:819-822.
  13. Dougherty JM, McCulley JP, Silvany RE, Meyer DR. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. Invest Ophthalmol Vis Sci. 1991;32:2970-2975.
  14. Joffre C, Souchier M, Gre´goire S, Viau S, Bretillon L, Acar N, Bron AM, Creuzot-Garcher C. Differences in meibomian fatty acidcomposition in patients with meibomian gland dyfunction and aqueous-deficient dry eye. Br J Ophthalmol. 2008;92:116-119.
  15. Dastjerdi MH, Hamrah P, Dana R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to tw